KNIGHT CAPITOL CONSULTANTS for REGENXBIO
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Potential legislation implementing value based purchasing for pharmaceuticals (HR 7389); Possible provisions related to Drug Pricing Legislation that affect biological products' development, approval, accelerated approval, and marketing, including deliberations associated with the Reauthorization of the Prescription Drug User Fee Act ( HR 7667) (S 4348), or the continuing resolution(Further Extendjnf Government Funding Act P.L. 117-70. Possible drug pricing legislation included in any budget reconciliation legislation ( no specific number). Reauthorization of the Newborn Screening Saves Lives Act (HR 482, S 350.)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch |
Medicare/Medicaid MMM
Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Pharmacy PHA
Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Taxation/Internal Revenue Code TAX
Potential changes in the corporate tax rate or other provisions of interest to business (Build Back Better Act, H.R. 5376 or any successor budget reconciliation legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.